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Table 1
Donor Demographics and Outcomes
Initial
Clearance
N¼15
Not Initially
Cleared
N¼47
Males 8 53% 23 49%
Age median (range) 47 (22-66) 49 (20-72)
Family
Single Donor Family 14 93% 38 81%
Multi Donor Family 1 7% 9 19%
Type
Haplo-identical 3 20% 11 23%
Identical 12 80% 36 77%
Foreign Born 1 7% 13 28%
Donated
Yes 13 87% 31 66%
Ineligible but donated 0 4
Ineligible for PBSC 1 2
No 2 13% 16 34%
Ineligible & Deferred 0 7
More suitable donor 2 2
Recipient delay 0 3
Incomplete clearance 0 2
Change in protocol 0 1
Lab abnormalities 0 1
Product
PBSC 4 31% 25 81%
BM 2 15% 4 13%
MD requested 1 2
Per NMDP 1 2
Lymphocytes 6 46% 1 3%
Combination 1 (PB and BM) 8% 1 (PB and
Lymph)
3%
End Eligibility
Eligible and donated 13 87% 27 57%
Ineligible and donated 0 4 9%
Eligible and did not donate 2 13% 5 11%
Ineligible and did not
donate
0 8 17%
Incomplete Eligibility 0 3 6%
Abbreviations: PBSC e Peripheral Blood Stem Cells; BM e Bone Marrow
Table 2
Additional Evaluations
Abnormal Consult Further Testing
EKG 15 13 3
Pits 5 5 4
LFTs 15 10 9
X-Ray 2 2 1
Urinalysis 10 4 8
Other 8
Abbreviations: EKG e Electrocardiogram; Pits e Platelets, LFTs e Liver
Function Tests, Neuro e Neurology
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more complex and resource demanding. 2) Care should be
taken in selecting donors for screening to avoid unnecessary
added costs to the transplant.369
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Background: Late cytomegalovirus (CMV) disease occurs in
about 6% of patients (R+ or D+/R-) who survive the ﬁrst threemonths after HCT. We have previously identiﬁed steroid
treatment after day 100 and CMV viremia before and after
day 100 as risk factors for late CMV disease. Little is known,
however, about the epidemiology and risk factors of
recurrent late CMV disease. The objectives of this study were
to describe the incidence, clinical characteristics, outcome,
and risk factors for the development of recurrent late CMV
disease.
Methods: We retrospectively analyzed medical records of
117 HCT patients, who developed CMV disease more than
100 days after their ﬁrst allogeneic HCT between 2001 and
2011.We evaluated all CMV disease events occurring be-
tween the ﬁrst late CMV disease and 2 years after HCT. Late
CMV diseasewas considered recurrent if it occurred at least 6
weeks after the ﬁrst late CMV disease.
Results: Among 117 patients with late CMV disease, 31
(26%) patients died within 6 weeks of diagnosis. Twelve of
the eighty-six (14%) surviving patients developed a sec-
ond late CMV disease event. Nine (75%) of the second late
CMV disease cases were observed in the same organ,
while three (25%) occurred in a different organ. There
were 6 (50%) cases of gastrointestinal (GI) disease, 5 (42%)
cases of pneumonia, and 1 (8%) episode of retinitis. Sec-
ond late CMV disease episodes occurred at a median of
147 days [range 52-351] after the ﬁrst late CMV disease
and 374 days [range 212-679] after HCT. In addition, there
were 4 cases of third late CMV disease (3 pneumonia
and 1 GI).
All of the patients were receiving systemic immunosup-
pressive therapies at the time they developed recurrent late
CMV disease. Nine of these twelve patients were undergoing
weekly surveillance for viremia by PCR testing after their ﬁrst
late CMV disease event. Two patients developed CMV disease
while receiving preemptive therapy for viremia. Three pa-
tients had low-level viremia below the threshold for starting
treatment. However, four (33%) of the recurrent late CMV
disease events (2 pneumonia, 2 GI) developed in the absence
of viremia.
Two (17%) of the 12 patients with recurrent late CMV
disease died within 6 weeks of their diagnosis; one addi-
tional patient died shortly after developing a third episode of
CMV disease, and the remaining 9 patients survived at least
to two years after HCT.
Conclusions: These data demonstrate that recurrent late
CMV disease is not a rare event after allogeneic HCT. Patients
who remain on systemic immunosuppressive therapy after a
ﬁrst episode of late CMV disease seem to be at particularly
high risk for recurrence. While preemptive treatment of
viremia might prevent some of these events, one-third of the
cases developed in the absence of viremia including 2 cases
of CMV pneumonia. Further study is warranted to prevent
the morbidity and mortality associated with this late
complication of HCT.TRANSPLANT DATA MANAGEMENT370
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In order to justify the resources to build an in-house database
we performed a GAP analysis, Scope, Requirements, Schema
andDashboard Design assessment and plan. The GAP analysis
identiﬁed the gap between current data ﬁelds and new data
ﬁelds needed. Over 3200 ﬁelds are required to enter data for
40 CIBMTR forms. The GAP analysis included the following: 1)
source of the data, 2) discreteness of the data, and 3) data
interface capability versus manual entry required. The Scope
of the project contained an Executive Summary describing
the number of patients transplanted annually, the data
sources, purposes of the data, current system limitation, and
the number of additional FTE’s needed to meet Continuous
Process Improvement (CPI) if no new database system was
devised. In addition to identiﬁcation of systems to be
replaced, users of the database, consumers of the data,
project goals, new interfaces required, and migration of leg-
acy data were assessed. A requirements document described
the data and interface needs. This document consisted of the
tables and their ﬁelds that would go into the database as well
as the design of the screens. It also described how the data
would be interfaced through staging tables from the Hospital
Electronic Medical Record (EMR) to the Data warehouse to
BMT Research and Analysis Informatics Network (BRAIN). A
description of a dashboard was included for management of
the CIBMTR forms that were due for each patient. Diagrams
presented illustrate patient ﬂow through our program,
CIBMTR forms submission timeline, and the data ﬂow into
and from our database before and after the new system
development.
Complete and thorough documentation is necessary to
provide an audience of hospital and IT management an
understanding of why a new database system is needed.
Documentation reported the present state and its
current problems and justiﬁed development of a new
database system providing for future growth and
ﬂexibility.Figure 1. A partial view of the BMT Da371
Microsoft Access: A Viable Blood and Marrow
Transplant (BMT) Database Solution
Lindsay Dozeman, Alison Amendola, Connie Grobe,
Lisa Cantwell. Blood and Marrow Transplant, The University of
Iowa Hospitals and Clinics, Iowa City, IA
Background: Accurate and efﬁcient BMT data collection is
essential for outcomes analyses and program administration
as well as for meeting external reporting requirements. As
technological innovation has driven the transition from
paper-based charts to electronic medical records (EMRs), a
rapid development of software products designed to work
alongside EMRs has taken place to provide programs with
the ability to analyze and manipulate their electronic data in
real-time. Although promising efforts are underway to
improve current products and to integrate separate systems
into one EMR platform, BMT programs may determine that a
customizable database is needed to fulﬁll their present data
needs until a more comprehensive solution arises. Our
program turned to Microsoft Access to create a
BMT-speciﬁc database to fulﬁll our current data needs while
we continue to advance development of program-speciﬁc
solutions within Epic, our hospital's EMR.
Methods: A spreadsheet of all transplants performed and the
transplant essential data available from CIBMTR's Data Back
to Centers (DBtC) portal were translated and uploaded into a
Microsoft Access database. A main data entry form was
created to minimize errors and maximize efﬁciency of all
necessary TED data required by the local program and
CIBMTR. Combo boxes, validation properties, and simple
Visual Basic (VBA) events were added to maximize func-
tionality and standardize the data at the time of ﬁrst entry.
Tabs within themain form organize data by logical order, and
a hyperlink can be clicked to bring the user to CIBMTR's
reporting manuals. A separate form similar in appearance to
the form 2450 was created to view all previously reportedta Team's main data entry form.
